Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Phase 1 trial of edaravone in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point at 48 hours, Area Under the Plasma Concentration Versus Time Curve From Time Zero up to Infinity at 48 hours and 1 more. Started Mar 2019; status: completed.